Document Detail

Hemorrhagic pseudoaneurysm in a patient receiving aflibercept for metastatic thyroid cancer.
MedLine Citation:
PMID:  22510046     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Agents such as aflibercept, which target the angiogenic pathway, are of great interest as candidates for the management of metastatic differentiated thyroid cancer. Here, we report a patient who developed a hemorrhagic abdominal pseudoaneurysm shortly after being started on this drug.
PATIENT FINDINGS: The patient was a 67-year-old woman being treated with single agent aflibercept (VEGF-Trap) for metastatic thyroid cancer. She had no history of intra-abdominal pathology or vascular disease but had been previously treated with sorafenib. Twelve days after receiving her second dose of aflibercept, she developed vague abdominal pain, which increased in severity and was accompanied by nausea and vomiting. Her symptoms progressed along with a decline in her hematocrit and signs of internal hemorrhaging. An angiogram identified an occluded celiac artery with increased collaterals and a bleeding pseudoaneurysm in the inferior pancreaticoduodenal artery. After the pseudoaneurysm was coiled, the patient stabilized.
SUMMARY AND CONCLUSIONS: Anti-angiogenic agents, usually well tolerated, can disrupt the delicate balance of normal endothelium, leading to hemorrhagic and thrombotic complications. The hemorrhage of aberrant vasculature should be included in the differential diagnosis in patients presenting with vague complaints while being treated with anti-angiogenic agents.
Shrujal S Baxi; Eric J Sherman; Katherine W Kelly; Karen T Brown; Ronald P Dematteo; David G Pfister
Related Documents :
25295656 - Risk factors associated with hypogonadism in β-thalassemia major patients: predictors ...
15893406 - Csf hypocretin-1/orexin-a concentrations in patients with subarachnoid hemorrhage (sah).
25254006 - Evaluation of clinico-epidemiological and histopathological features of pityriasis rosea.
19231066 - A priority treatment of the intraventricular hemorrhage (ivh) should be performed in th...
8167556 - Monocyte tissue factor in treated hodgkin's disease.
6743946 - Psychophysiological responses of schizophrenic patients to high and low expressed emoti...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-04-17
Journal Detail:
Title:  Thyroid : official journal of the American Thyroid Association     Volume:  22     ISSN:  1557-9077     ISO Abbreviation:  Thyroid     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-01     Completed Date:  2012-09-05     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9104317     Medline TA:  Thyroid     Country:  United States    
Other Details:
Languages:  eng     Pagination:  552-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aneurysm, False / complications,  etiology*
Angiogenesis Inhibitors / pharmacology
Angiography / methods
Duodenum / blood supply
Hemorrhage / complications,  etiology*
Neoplasm Metastasis
Pancreas / blood supply
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins / therapeutic use*
Thyroid Neoplasms / complications,  drug therapy*,  pathology*
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Recombinant Fusion Proteins; 15C2VL427D/aflibercept; EC, Vascular Endothelial Growth Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of scaling and root planing on interleukin-1?, interleukin-8 and MMP-8 levels in gingival cre...
Next Document:  Postoperative adverse outcomes in surgical patients with epilepsy: A population-based study.